Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model

AJ Kunz Coyne, C Bleick, K Stamper… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Phage-antibiotic combinations (PAC) offer a potential solution for treating refractory
daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) …
相关文章

Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model.

KC AJ, C Bleick, K Stamper, R Kebriaei… - Antimicrobial Agents …, 2024 - europepmc.org
Phage-antibiotic combinations (PAC) offer a potential solution for treating refractory
daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) …

Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model

AJK Coyne, C Bleick, K Stamper… - Antimicrobial …, 2024 - pubmed.ncbi.nlm.nih.gov
Phage-antibiotic combinations (PAC) offer a potential solution for treating refractory
daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) …

Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model.

KC AJ, C Bleick, K Stamper, R Kebriaei… - Antimicrobial Agents …, 2024 - europepmc.org
Phage-antibiotic combinations (PAC) offer a potential solution for treating refractory
daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) …